FDA Schedules Advisory Committee Meeting for Grail's Galleri Multi-Cancer Screening Test

Aug 7, 2026

The U.S. Food and Drug Administration has scheduled an advisory committee meeting on September 23, 2026, to review GRAIL's premarket approval application for its Galleri multi-cancer early detection blood test. The review follows mixed clinical trial results, including a large UK study that missed its primary endpoint but demonstrated secondary benefits in reducing stage IV diagnoses. GRAIL still targets FDA approval in early 2027, which could unlock a legislative pathway for Medicare coverage starting in 2029.

FDA advisory committee meeting

▪The U.S. Food and Drug Administration's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on September 23, 2026 to review the Premarket Approval application for GRAIL's Galleri multi-cancer early detection blood test.
▪The Food and Drug Administration is not legally required to follow the recommendations of its advisory panels when reviewing medical devices.

Galleri methylation detection technology

▪The Galleri test is intended to be used in addition to, and not as a replacement for, guideline-recommended cancer screenings such as mammograms and colonoscopies.
▪GRAIL's Galleri test is designed to detect cancer-specific methylation patterns shared by many types of cancer in the bloodstream before symptoms appear.

UK clinical trial results

▪Full results from the UK trial presented in May showed that by the third round of screening, the Galleri test reduced stage IV cancer diagnoses by 26% for 12 deadly cancers and increased cancer detection fourfold compared with standard screening alone.
▪A three-year UK trial of GRAIL's Galleri test in asymptomatic adults aged 50 to 77 years failed to meet its primary endpoint of significantly reducing late-stage cancer diagnoses or improving early detection compared to standard care.

Premarket approval timeline

▪GRAIL management continues to expect potential Food and Drug Administration approval for the Galleri test in the first part of 2027.
▪GRAIL submitted its Premarket Approval application for the Galleri test to the Food and Drug Administration on January 29, 2026.

Medicare reimbursement pathway

▪Analysts have questioned the reimbursement prospects for GRAIL's Galleri test despite the legislative pathway established for Medicare coverage.
▪A January U.S. congressional funding bill created a pathway for Medicare coverage of Food and Drug Administration-approved multi-cancer early detection tests for individuals aged 50 to 65 starting in 2029, subject to clinical benefit.